Market Cap (In TWD)
4.13 Billion
Revenue (In TWD)
24.58 Million
Net Income (In TWD)
-84.1 Million
Avg. Volume
16.12 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 68.0-88.0
- PE
- -
- EPS
- -
- Beta Value
- -0.314
- ISIN
- -
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- -
- Employee Count
- -
- Website
- https://www.unicocell.com
- Ipo Date
- 2024-05-13
- Details
- UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs, cell therapy technology, and regenerative medical services in Taiwan. It develops ELIXCYTE, which is in Phase 2 clinical trials for the treatment of osteoarthritis and chronic kidney disease. The company offers UnicoVial, a cryotube and drug container for cell therapy products, as well as provides testing services. UnicoCell Biomed Co., Ltd. is based in Taipei, Taiwan.
More Stocks
-
7607
-
MC
-
GRATGratomic Inc.
GRAT
-
SVT
-
WTBFA
-
USEA
-
UGP
-
MSP